Healthcare of Ontario Pension Plan Trust Fund Raises Stock Position in Collegium Pharmaceutical, Inc. $COLL

Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 49.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 61,742 shares of the specialty pharmaceutical company’s stock after purchasing an additional 20,540 shares during the period. Healthcare of Ontario Pension Plan Trust Fund owned about 0.19% of Collegium Pharmaceutical worth $2,042,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Vident Advisory LLC lifted its holdings in shares of Collegium Pharmaceutical by 1.9% in the 3rd quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company’s stock valued at $541,000 after buying an additional 281 shares during the period. Quadrant Capital Group LLC raised its position in Collegium Pharmaceutical by 4.2% during the fourth quarter. Quadrant Capital Group LLC now owns 6,996 shares of the specialty pharmaceutical company’s stock valued at $324,000 after acquiring an additional 282 shares in the last quarter. Atom Investors LP lifted its holdings in Collegium Pharmaceutical by 5.0% in the fourth quarter. Atom Investors LP now owns 6,124 shares of the specialty pharmaceutical company’s stock valued at $284,000 after acquiring an additional 294 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in Collegium Pharmaceutical by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock worth $71,000 after purchasing an additional 318 shares in the last quarter. Finally, Assetmark Inc. grew its stake in shares of Collegium Pharmaceutical by 9.3% during the 1st quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company’s stock worth $130,000 after purchasing an additional 335 shares during the period.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Wall Street Zen lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. Zacks Research cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Truist Financial upgraded Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Collegium Pharmaceutical in a report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL opened at $35.39 on Friday. The company has a debt-to-equity ratio of 2.47, a quick ratio of 1.62 and a current ratio of 1.71. The stock has a market capitalization of $1.15 billion, a PE ratio of 17.35 and a beta of 0.73. Collegium Pharmaceutical, Inc. has a fifty-two week low of $29.19 and a fifty-two week high of $50.79. The company has a fifty day moving average of $34.84 and a two-hundred day moving average of $37.55.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.52 by $0.24. The business had revenue of $193.52 million for the quarter, compared to analyst estimates of $184.47 million. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The company’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter last year, the business earned $1.49 earnings per share. As a group, research analysts forecast that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.